IDEAS home Printed from https://ideas.repec.org/h/nbr/nberch/9894.html
   My bibliography  Save this book chapter

Pharmaceutical Innovation and US Cancer Survival, 1992-2003: Evidence from Linked SEER-MEDSTAT Data

In: Frontiers in Health Policy Research, Volume 10

Author

Listed:
  • Frank R. Lichtenberg

Abstract

This study examines the impact of pharmaceutical innovation and other factors on the survival of U.S. cancer patients during the period 1992-2003. In particular, it investigates whether cancer survival rates increased more for those cancer sites that had the largest increases in the proportion of chemotherapy treatments that were "new" treatments. We control for other types of medical innovation, i.e. other pharmaceutical innovation, and innovation in surgical procedures, diagnostic radiology procedures, and radiation oncology procedures.Data on observed survival rates, the number of people diagnosed, mean age at diagnosis, and stage distribution are obtained from the National Cancer Institute's SEER public-use data. Estimates of rates of innovation in chemotherapy and other treatment and diagnostic procedures are constructed from the MEDSTAT MarketScan database and other data sources. Treatment innovation indicators based on MEDSTAT data are likely to be useful, albeit noisy, indicators of the treatment innovation experienced by patients in SEER registries. This sampling error is likely to bias the coefficients on the treatment innovation measures towards zero.We compute weighted least-squares estimates of 6 versions of a survival model, based on different survival intervals and functional forms. The chemotherapy vintage coefficient is positive and significant in every model. This indicates that the cancer sites whose chemotherapy vintage (measured by the share of post-1990 treatments) increased the most during the period 1992-2003 tended to have larger increases in observed survival rates, ceteris paribus.We estimate how much lower the survival rate from all cancer sites combined would have been during 1993-2001 in the absence of post-1992 chemotherapy innovation. The estimates indicate that chemotherapy innovation accounted for 74% of the increase in the 1-year observed survival rate for all cancer sites combined during the period 1992-2001. Chemotherap
(This abstract was borrowed from another version of this item.)

Suggested Citation

  • Frank R. Lichtenberg, 2007. "Pharmaceutical Innovation and US Cancer Survival, 1992-2003: Evidence from Linked SEER-MEDSTAT Data," NBER Chapters, in: Frontiers in Health Policy Research, Volume 10, National Bureau of Economic Research, Inc.
    • Handle: RePEc:nbr:nberch:9894
    as

    Download full text from publisher

    To our knowledge, this item is not available for download. To find whether it is available, there are three options:
    1. Check below whether another version of this item is available online.
    2. Check on the provider's web page whether it is in fact available.
    3. Perform a search for a similarly titled item that would be available.

    Other versions of this item:

    References listed on IDEAS

    as
    1. Frank R. Lichtenberg, 2004. "The expanding pharmaceutical arsenal in the war on cancer," 2004 Meeting Papers 204, Society for Economic Dynamics.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Frank R. Lichtenberg, 2014. "Has Medical Innovation Reduced Cancer Mortality?," CESifo Economic Studies, CESifo Group, vol. 60(1), pages 135-177.
    2. Vincenzo Atella & Francesco D'Amico, 2010. "Who is responsible for your health: You, your doctor or new technologies?," CEIS Research Paper 167, Tor Vergata University, CEIS, revised 28 May 2010.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Lakdawalla, Darius N. & Sun, Eric C. & Jena, Anupam B. & Reyes, Carolina M. & Goldman, Dana P. & Philipson, Tomas J., 2010. "An economic evaluation of the war on cancer," Journal of Health Economics, Elsevier, vol. 29(3), pages 333-346, May.
    2. Martin, Stephen & Rice, Nigel & Smith, Peter C., 2008. "Does health care spending improve health outcomes? Evidence from English programme budgeting data," Journal of Health Economics, Elsevier, vol. 27(4), pages 826-842, July.
    3. Kyle, Margaret & Dubois, Pierre, 2016. "The Effects of Pharmaceutical Innovation on Cancer Mortality," CEPR Discussion Papers 11487, C.E.P.R. Discussion Papers.
    4. Dolan, Paul & Metcalfe, Robert, 2012. "The relationship between innovation and subjective wellbeing," Research Policy, Elsevier, vol. 41(8), pages 1489-1498.
    5. Lionel Perrier & Magali Morelle & Nathalie Havet & Anthony Montella & Bertrand Favier & David Perol & Frédéric Gomez & Marie-Odile Carrere & Paul Rebattu, 2009. "The effect of health care expenditures on survival in locally advanced and metastatic Non Small Cell Lung Cancer," Working Papers 0903, Groupe d'Analyse et de Théorie Economique Lyon St-Étienne (GATE Lyon St-Étienne), Université de Lyon.
    6. Fabio Pammolli & Massimo Riccaboni & Nicola Carmine Salerno, 2012. "I Farmaci Oncologici in Italia: innovazione e sostenibilità economica," Working Papers CERM 02-2012, Competitività, Regole, Mercati (CERM).
    7. Dubois, Pierre & Kyle, Margaret, 2016. "The Effects of Pharmaceutical Innovation on Cancer Mortality Rates," TSE Working Papers 16-688, Toulouse School of Economics (TSE).
    8. Okunade, Albert A., 2004. "Concepts, measures, and models of technology and technical progress in medical care and health economics," The Quarterly Review of Economics and Finance, Elsevier, vol. 44(3), pages 363-368, July.
    9. Rosarin Sruamsiri & Dennis Ross-Degnan & Christine Y Lu & Nathorn Chaiyakunapruk & Anita K Wagner, 2015. "Policies and Programs to Facilitate Access to Targeted Cancer Therapies in Thailand," PLOS ONE, Public Library of Science, vol. 10(3), pages 1-17, March.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nbr:nberch:9894. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: the person in charge (email available below). General contact details of provider: https://edirc.repec.org/data/nberrus.html .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.